文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

同步评估咽部与直肠淋球菌及沙眼衣原体诊断试验的主方案研究

Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究采用横断面单次访视设计,在7州9家诊所纳入2598名寻求性传播感染检测的成人,采集咽部和直肠拭子,以复合参考方法评估3种试验检测淋球菌和沙眼衣原体的性能。结果显示不同解剖部位感染组合的阳性符合率为84.8%至96.5%,阴性符合率为98.8%至99.6%,最终支持FDA首次批准用于非生殖部位检测的试验。

要点

  • 咽部和直肠淋球菌及沙眼衣原体感染在耐药传播中意义重要,本研究为此类部位检测试验的监管提交提供性能数据。
  • 研究采用主方案在单一人群中同步评估多厂家试验,阳性符合率84.8%至96.5%,阴性符合率98.8%至99.6%。
  • 该研究最终支持FDA首次批准用于咽部和直肠标本的淋球菌及沙眼衣原体检测试验。

核心结论

  • 与复合参考方法相比,3种试验检测咽部和直肠淋球菌及沙眼衣原体均观察到很好的阳性符合率。
  • 该主方案研究生成的多厂家试验性能数据最终支持FDA首次批准用于非生殖部位检测的试验。

研究设计与样本

  • 横断面单次访视研究,在7个州的9家诊所纳入寻求性传播感染检测的成人。
  • 共2598名参与者接受检测,其中79%为男性。
  • 采集咽部和直肠拭子,以复合参考方法比较3种研究性试验的阳性与阴性符合率。

主要发现

  • 咽部淋球菌阳性率为8.1%,直肠淋球菌阳性率为7.9%。
  • 咽部沙眼衣原体阳性率为2.0%,直肠沙眼衣原体阳性率为8.7%。
  • 不同解剖部位感染组合的阳性符合率范围为84.8%至96.5%,阴性符合率范围为98.8%至99.6%。

临床怎么用

  • 研究支持的检测试验可用于咽部和直肠淋球菌及沙眼衣原体感染的诊断评估。
  • 临床可依据不同解剖部位的阳性符合率与阴性符合率数据理解检测性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis play important roles in infection and antibacterial resistance transmission, but no US Food and Drug Administration (FDA)-cleared assays for detection at these sites existed prior to this study. The objective was to estimate performance of assays to detect those infections in pharyngeal and rectal specimens to support regulatory submission. METHODS: We performed a cross-sectional, single-visit study of adults seeking sexually transmitted infection testing at 9 clinics in 7 states. We collected pharyngeal and rectal swabs from participants. The primary outcome was positive and negative percent agreement for detection of N. gonorrhoeae and C. trachomatis for 3 investigational assays compared to a composite reference. Secondary outcomes included positivity as well as positive and negative predictive values and likelihood ratios. Subgroup analyses included outcomes by symptom status and sex. RESULTS: A total of 2598 participants (79% male) underwent testing. We observed N. gonorrhoeae positivity of 8.1% in the pharynx and 7.9% in the rectum and C. trachomatis positivity of 2.0% in the pharynx and 8.7% in the rectum. Positive percent agreement ranged from 84.8% to 96.5% for different anatomic site infection combinations, whereas negative percent agreement was 98.8% to 99.6%. CONCLUSIONS: This study utilized a Master Protocol to generate diagnostic performance data for multiple assays from different manufacturers in a single study population, which ultimately supported first-in-class FDA clearance for extragenital assays. We observed very good positive percent agreement when compared to a composite reference method for the detection of both pharyngeal and rectal N. gonorrhoeae and C. trachomatis. CLINICAL TRIALS REGISTRATION: NCT02870101.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Doernberg SB, Komarow L, Tran TTT, et al. Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol. Clin Infect Dis. 2020. PMID: 31734695. doi:10.1093/cid/ciz1105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。